Mops Inhibitors
Chemical inhibitors of Mops can effectively disrupt its function by targeting various signaling pathways and kinases that regulate its activity. Staurosporine, a broad-spectrum kinase inhibitor, can inhibit Mops by halting the activity of kinases that phosphorylate proteins within the Mops signaling cascade, thereby preventing its activation. Similarly, Bisindolylmaleimide I and GF109203X both specifically inhibit protein kinase C (PKC), a kinase that potentially phosphorylates regulatory proteins upstream of Mops. This inhibition can lead to a decrease in Mops activity as the activation signals are reduced. LY294002 and Wortmannin exert their inhibitory effects on Mops through the blockade of phosphoinositide 3-kinases (PI3K), which are upstream regulators in the PI3K/Akt pathway, a pathway that can regulate Mops activity. By inhibiting PI3K, these chemicals prevent the subsequent activation of the Akt pathway and therefore the activity of Mops is decreased.
Continuing with pathway-specific inhibitors, PD98059 and U0126 both target MEK in the MAPK/ERK pathway, a pathway known to regulate proteins including Mops. Inhibition of MEK prevents the activation of downstream ERK, which in turn inhibits the activity of Mops. Additionally, SB203580, by inhibiting p38 MAPK, and SP600125, by inhibiting JNK, can decrease Mops activity by preventing the activation of these stress-activated MAPK pathways that may regulate Mops. Rapamycin, through its inhibition of mTOR, disrupts the PI3K/Akt/mTOR pathway, further inhibiting the activity of Mops as this pathway is a central regulator of protein function. Finally, Lapatinib and Sorafenib, both tyrosine kinase inhibitors, inhibit various tyrosine kinase receptors such as EGFR, HER2/neu, VEGFR, and PDGFR. By inhibiting these receptors, the chemicals interrupt the downstream signaling pathways that regulate Mops activity, leading to a decrease in its functional activity within the cell.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a wide range of protein kinases, which may include kinases within the signaling pathways that Mops is involved in. By inhibiting these kinases, the downstream signaling leading to Mops activation could be inhibited. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). Since PKC can phosphorylate proteins that are upstream or regulators of Mops, its inhibition can reduce Mops activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a kinase that participates in the Akt signaling pathway. As the PI3K/Akt pathway can regulate a variety of proteins including Mops, inhibition by LY294002 could reduce Mops activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 selectively inhibits MEK, which is part of the MAPK/ERK pathway. As the MAPK/ERK pathway can regulate proteins including Mops, PD98059 can inhibit Mops activity by blocking this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, a kinase that may regulate proteins upstream of Mops. Inhibition of p38 MAPK can lead to reduced Mops activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. Similar to LY294002, it can inhibit Mops activity by blocking the PI3K/Akt pathway, which may regulate Mops. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the stress-activated MAPK pathway. Through inhibition of JNK, SP600125 can lead to reduced activity of proteins that are regulated by this pathway, including Mops. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, key components of the MAPK/ERK pathway. By inhibiting this pathway, U0126 can diminish the activity of proteins that are regulated by MAPK/ERK signaling, including Mops. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, which is a central component of the PI3K/Akt/mTOR pathway. Since this pathway can regulate the activity of various proteins, including Mops, rapamycin can inhibit Mops activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits the tyrosine kinases EGFR and HER2/neu. By inhibiting these receptors, it can interfere with downstream signaling pathways that regulate proteins including Mops, leading to its inhibition. | ||||||